A Phase 1, Single Center, Randomized, Double-Blind, Placebo-Controlled, Single (Part 1) and Multiple (Part 2) Ascending Dose Study to Evaluate the Safety, Tolerability, PK and PD of M281 Administered to Healthy Volunteers

Trial Profile

A Phase 1, Single Center, Randomized, Double-Blind, Placebo-Controlled, Single (Part 1) and Multiple (Part 2) Ascending Dose Study to Evaluate the Safety, Tolerability, PK and PD of M281 Administered to Healthy Volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs M 281 (Primary)
  • Indications Autoimmune disorders
  • Focus Adverse reactions
  • Sponsors Momenta Pharmaceuticals
  • Most Recent Events

    • 02 Aug 2017 According to a Momenta Pharmaceuticals media release, the company expects to complete the multiple ascending dose portion of the study in August 2017.
    • 21 Feb 2017 According to a Momenta Pharmaceuticals media release, the company plans to report the full data from the single and multiple ascending dose portions of the study in the second half of 2017.
    • 06 Jan 2017 According to a Momenta Pharmaceuticals media release, the company has completed five cohorts in the single ascending dose (SAD) portion of the study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top